I don't think anyone can know what the holder of a .25ct warrant/option might do. What is certain is that the company has approximately $31 million in the bank which gets them to end of June or early July, and hopefully can raise another $15 million through additional conversions to carry them through August.
Attaching two articles. One a dual authored paper published in Science Magazine regarding the Cytokine release syndrome in severe CV-19 patients and the authors opinions of best drug therapy - and another from Endpoints newsletter that speaks to the FDA approving a couple of drugs early, prior to PDUFA dates. If the BLA is finally submitted by end of April I think we stand a decent chance of approval in four months- The FDA is very familiar with the efficacy & safety and should have already reviewed first portion-- No reason they can't stamp it approved in four months- And I hope we're on the NASDAQ prior to then to really watch the PPS take off